Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Addition of histone deacetylase inhibitors in combination therapy.

× No keyword cloud information.

10 in total

Review 1. Epigenetic alterations in osteosarcoma: promising targets.

Authors: Binghao Li; Zhaoming Ye
Journal: Mol Biol Rep Date: 2014-02-06 Impact factor: 2.316

2. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Authors: S L Locatelli; L Cleris; G G Stirparo; S Tartari; E Saba; M Pierdominici; W Malorni; A Carbone; A Anichini; C Carlo-Stella
Journal: Leukemia Date: 2014-02-24 Impact factor: 11.528

3. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

Authors: Hyun Chang; Sun Young Rha; Hei-Cheul Jeung; Jae-Jun Jung; Tae Soo Kim; Ho Jeong Kwon; Byung Soo Kim; Hyun Cheol Chung
Journal: J Cancer Res Clin Oncol Date: 2010-03-09 Impact factor: 4.553

Review 4. Newly emerging therapies targeting viral-related lymphomas.

Authors: Juan Carlos Ramos; Izidore S Lossos
Journal: Curr Oncol Rep Date: 2011-10 Impact factor: 5.075

5. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.

Authors: Luke A Wittenburg; Liam Bisson; Barbara J Rose; Christopher Korch; Douglas H Thamm
Journal: Cancer Chemother Pharmacol Date: 2010-03-20 Impact factor: 3.333

6. Melanoma: a model for testing new agents in combination therapies.

Authors: Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal: J Transl Med Date: 2010-04-20 Impact factor: 5.531

7. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Authors: Shruti Bhatt; Brittany M Ashlock; Ngoc L Toomey; Luis A Diaz; Enrique A Mesri; Izidore S Lossos; Juan Carlos Ramos
Journal: J Clin Invest Date: 2013-05-01 Impact factor: 14.808

8. A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.

Authors: Seung Ah Choi; Pil Ae Kwak; Chul-Kee Park; Kyu-Chang Wang; Ji Hoon Phi; Ji Yeoun Lee; Chang Sik Lee; Ju-Hee Lee; Seung-Ki Kim
Journal: Oncotarget Date: 2017-02-07

9. Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.

Authors: Yuwen He; Danyang Chen; Yanmei Yi; Shanshan Zeng; Shuang Liu; Pan Li; Hui Xie; Pengjiu Yu; Guanmin Jiang; Hao Liu
Journal: Mol Ther Oncolytics Date: 2020-05-08 Impact factor: 7.200

10. Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines.

Authors: Venugopal Thayanithy; ChangWon Park; Aaron L Sarver; Reena V Kartha; Derek M Korpela; Ashley J Graef; Clifford J Steer; Jaime F Modiano; Subbaya Subramanian
Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240

10 in total